A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

The stock's fall snapped a four-day winning streak.

Several companies across various sectors on the Wall Street have seen some Seeking Alpha analyst activity, including both ...

Helping Veterans and Families (HVAF), in partnership with the Indiana Department of Veterans Affairs and Workforce ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...